Neuren Pharmaceuticals (ASX:NEU) Receipts from Customers: A$65.58 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:NEU Neuren Pharmaceuticals Ltd ASX:NEU
53 GF Score
Price A$20.45
GF Value A$7.52
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Neuren Pharmaceuticals Receipts from Customers?

Neuren Pharmaceuticals ASX:NEU -2.71% 53 Receipts from Customers is A$65.58 Mil as of Jun. 2026. GuruFocus rates ASX:NEU with a GF Score™ of 53/100 and a GF Value™ of A$7.52 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Neuren Pharmaceuticals's Receipts from Customers for the six months ended in Jun. 2026 was A$34.41 Mil.

Neuren Pharmaceuticals's Receipts from Customers for the trailing twelve months (TTM) ended in Jun. 2026 was A$65.58 Mil.

Neuren Pharmaceuticals Receipts from Customers Historical Data

* Premium members only.

The historical data trend for Neuren Pharmaceuticals's Receipts from Customers can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuren Pharmaceuticals Receipts from Customers Chart

Neuren Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Receipts from Customers
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 15.92 221.00 51.42 222.50

Neuren Pharmaceuticals Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Receipts from Customers Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.43 26.99 191.34 31.16 34.41
ASX:NEU
53GF Score
Neuren Pharmaceuticals Ltd ASX:NEU
Receipts from Customers is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuren Pharmaceuticals Receipts from Customers Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Receipts from Customers represents payment received from customers in the direct cash flow method.

Receipts from Customers for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$65.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Receipts from Customers of A$65.58 Mil mean?
Neuren Pharmaceuticals (ASX:NEU) has a Receipts from Customers of A$65.58 Mil as of Jun. 2026. Receipts from Customers represents payment received from customers in the direct cash flow method. View historical data for Neuren Pharmaceuticals and its competitors.
Is Neuren Pharmaceuticals' Receipts from Customers too high?
Neuren Pharmaceuticals' current Receipts from Customers is A$65.58 Mil. Overall, Neuren Pharmaceuticals has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' Receipts from Customers compare to VRTX and REGN?
Neuren Pharmaceuticals' Receipts from Customers of A$65.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receipts from Customers for a Biotechnology company?
A good Receipts from Customers depends on the Biotechnology industry context. However, Receipts from Customers should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receipts from Customers mean?
A high Receipts from Customers can signal that a stock is expensive relative to its fundamentals. Receipts from Customers represents payment received from customers in the direct cash flow method. View historical data for Neuren Pharmaceuticals and its competitors. Neuren Pharmaceuticals's current Receipts from Customers is A$65.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (ASX:NEU) is currently considered Significantly Overvalued. The stock's GF Value™ is A$7.52, compared to a current price of A$20.45 — trading 171.9% above its estimated fair value. The current Receipts from Customers is A$65.58 Mil. Neuren Pharmaceuticals' overall GF Score™ is 53/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receipts from Customers calculated?
Receipts from Customers is calculated from a company's financial statements. For Neuren Pharmaceuticals (ASX:NEU), the current Receipts from Customers is A$65.58 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuren Pharmaceuticals (ASX:NEU) Overvalued in 2026?

Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued. The current stock price of A$20.45 is trading 171.9% above its estimated GF Value™ of A$7.52. GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ASX:NEU:

  • Receipts from Customers: A$65.58 Mil
  • GF Value™: A$7.52 vs. price of A$20.45 (171.9% above fair value)
  • GF Score™: 53/100 with 1 warning sign

No single metric tells the full story. See the ASX:NEU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuren Pharmaceuticals Business Description

Other Exchanges NURPF:USANK9:Germany
Address 117 Camberwell Road, Suite 1.01, Hawthorn East, Melbourne, VIC, AUS, 3123
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
53GF Score

Get the complete analysis for ASX:NEU

Receipts from Customers is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$20.45
Price
A$7.52
GF Value